Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurogene Inc. - Common Stock (NQ:NGNE)

18.34 +1.13 (+6.57%)
Streaming Delayed Price Updated: 2:08 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurogene Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Neurogene to Participate in Upcoming Investor Conferences
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
From Neurogene Inc.
Via Business Wire
News headline image
4 Biotech Stocks Seeing Explosive Momentum Gains ↗
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be... 
Via Benzinga
Topics ETFs Stocks
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact. 
Via Benzinga
News headline image
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction ↗
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Which stocks are moving on Tuesday? ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
From Neurogene Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.